The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer

BACKGROUND: An effect of non-oncology medications on cancer outcome has been proposed. In this study, we aimed to systematically examine the impact of commonly prescribed non-oncology drugs on clinical risk and on the genomic risk [based on the Oncotype DX recurrence score (RS)] in early breast canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Waissengrin, B., Zahavi, T., Salmon-Divon, M., Goldberg, A., Wolf, I., Rubinek, T., Winkler, T., Farkash, O., Grinshpun, A., Zubkov, A., Khatib, M., Shachar, S.S., Keren, N., Carmi-Levy, I., Ben-David, U., Sonnenblick, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808449/
https://www.ncbi.nlm.nih.gov/pubmed/36462463
http://dx.doi.org/10.1016/j.esmoop.2022.100648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808449/
https://www.ncbi.nlm.nih.gov/pubmed/36462463
http://dx.doi.org/10.1016/j.esmoop.2022.100648

Ejemplares similares